Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

574
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
574
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

469
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
469
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

146
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
146
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

129
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
129
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

301
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
301
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

162
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
162

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phosphate Disorders in Cancer.

Kidney360·2026
Same author

Cancer therapy and the kidney.

Kidney international·2026
Same author

Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death.

JCI insight·2026
Same author

Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.

Cancer treatment reviews·2025
Same author

More on Selpercatinib and Pseudo-Decreases in Kidney Function. Reply.

The New England journal of medicine·2025
Same author

Renal involvement in solid cancers: epidemiological, clinical and histological characteristics study of 154 onconephrology patients.

BMC nephrology·2024

Related Experiment Video

Updated: Mar 24, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

[Lenalidomide nephrotoxicity].

Rania Kheder El-Fekih1, Hassan Izzedine2

  • 1La Rabta Hospital, service de néphrologie, Tunis, Tunisie.

Bulletin Du Cancer
|March 2, 2016
PubMed
Summary

Lenalidomide is a key treatment for multiple myeloma but can cause kidney injury. This review covers its kidney effects and suggests dosage adjustments for patients with impaired renal function.

Keywords:
Acute interstitial nephritisAcute kidney injuryAdverse eventEffets indésirablesInsuffisance rénale aiguëLenalidomideLénalidomideMultiple myelomaMyélome multipleNephrotoxicityNéphrite interstitielle aiguëNéphrotoxicitéRhabdomyolyseRhabdomyolysis

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.5K
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K

Related Experiment Videos

Last Updated: Mar 24, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.5K
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K

Area of Science:

  • Pharmacology
  • Nephrology
  • Hematology

Background:

  • Lenalidomide is a vital therapy for multiple myeloma.
  • Lenalidomide use is linked to significant renal toxicity.
  • Managing lenalidomide requires understanding its renal impact.

Purpose of the Study:

  • To review lenalidomide pharmacokinetics and renal adverse effects.
  • To provide guidance on lenalidomide dosage adjustments in renal impairment.
  • To enhance the safe use of lenalidomide in hematologic malignancies.

Main Methods:

  • Literature review of lenalidomide pharmacokinetics.
  • Analysis of reported adverse renal events associated with lenalidomide.
  • Formulation of dosage adjustment recommendations based on renal function.

Main Results:

  • Lenalidomide undergoes renal excretion, necessitating dose modification.
  • Adverse renal effects range from mild dysfunction to acute kidney injury.
  • Specific pharmacokinetic data informs safe dosing strategies.

Conclusions:

  • Lenalidomide dosing requires careful consideration of renal function.
  • Monitoring renal function is crucial during lenalidomide therapy.
  • Dosage adjustments are essential to mitigate lenalidomide-induced kidney injury.